Search
Research
The potential of antisense oligonucleotide therapies for inherited childhood lung diseasesAntisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or overcome a patient's genetic mutation, in particular those lesions that compromise normal pre-mRNA processing. Antisense oligonucleotides can alter gene expression through a variety of mechanisms as determined by the chemistry and antisense oligomer design.
News & Events
Respiratory researcher named joint winner of prestigious Premier’s Science AwardCongratulations to respiratory health researcher and clinician Dr Pam Laird, who was last night named joint winner of Early Career Scientist of the Year at the 2024 Premier’s Science Awards.
News & Events
Toxic, harmful chemicals found in popular Australian e-liquidsPerth researchers have found toxic and harmful chemicals in several dozen e-cigarette liquids readily available in Australia.
Representing a 30-year interdisciplinary collaboration between The Kids, Perth Children’s Hospital, and WA Universities, the combined global impact of work from this Centre over the last 10 years has equalled some of the most influential paediatric centres around the world.
The Respiratory Physiology Platform at the Wal-yan Respiratory Research Centre offers access to specialist equipment housed within the outpatient research department at Perth Children’s Hospital, dedicated for research use.